复星医药(600196.SH)控股子公司药品SRT-003-1获临床试验批准

智通财经
Yesterday

智通财经APP讯,复星医药(600196.SH)发布公告,近日,公司控股子公司成都星睿菁烜生物科技有限公司(简称“星睿菁烜”)收到国家药品监督管理局关于同意[ 18F]F-SR031 注射液(简称“SRT-003-1”)用于实体瘤患者成纤维细胞活化蛋白(FAP)阳性病灶正电子发射断层扫描(PET)显像的临床试验批准。星睿菁烜拟于条件具备后于中国境内开展该药品的 I 期临床研究。

SRT-003-1 系靶向成纤维细胞活化蛋白(fibroblast activation protein,FAP)的放射性体内诊断药物,拟主要用于实体瘤患者 FAP 阳性病灶的PET 显像。FAP系Ⅱ型跨膜丝氨酸蛋白酶,属于脯氨酰寡肽酶家族,其在正常组织中几乎不表达,而在胃癌、食管癌、肺癌、结直肠癌、卵巢癌等多种上皮性肿瘤的肿瘤相关成纤维细胞(cancer-associated fibroblasts,CAF)中选择性高表达。以氟[ 18F]标记的FAP抑制剂可与 CAF 表面的 FAP 特异性结合,使 FAP 高表达的肿瘤病灶在PET 显像中呈高摄取,从而用于肿瘤的诊断、分期及疗效评估。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10